BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 5:39:00 PM | Browse: 413 | Download: 303
Publication Name World Journal of Orthopedics
Manuscript ID 1799
Country/Territory Japan
2013-01-07 09:49
Peer-Review Started
2013-01-07 17:01
To Make the First Decision
2013-02-21 21:51
Return for Revision
2013-02-27 10:19
2013-05-21 10:00
Second Decision
2013-06-19 12:53
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-06-20 00:50
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-09-16 10:41
Publish the Manuscript Online
2013-10-28 15:24
ISSN 2218-5836 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology and Metabolism
Manuscript Type Review
Article Title RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases
Manuscript Source Invited Manuscript
All Author List Hisataka Yasuda
Funding Agency and Grant Number
Corresponding author Hisataka Yasuda, PhD, Bioindustry Division, Oriental Yeast Co., Ltd., 3-6-10 Azusawa, Itabashi-ku, Tokyo 174-8505, Japan. yasuda.hisataka@nisshin.com
Keywords Osteoclast; Osteoblast; Receptor activator of nuclear factor-B ligand; Denosumab; Receptor activator of nuclear factor-B; Osteoprotegerin
Core Tip This review describes a success story from discovery of osteoprotegerin/receptor activator of nuclear factor-?B ligand (RANKL)/receptor activator of nuclear factor-?B (RANK) to clinical application of a fully human anti-RANKL monoclonal antibody to the treatment of osteoporosis and cancer-related bone disorders. RANKL is a key molecule for osteoclast differentiation and activation. Inhibition of RANKL activity with anti-RANKL antibody reduces osteoclastogenesis, resulting in inhibition of bone resorption. Three animal disease models of osteoporosis, hypercalcemia, and osteopetrosis by treating normal mice with soluble RANKL (sRANKL), adenovirus expressing sRANKL, and anti-mouse RANKL neutralizing antibody, respectively, can be established in 2-14 d and the establishment of these animal models could help accelerate research on bone metabolism.
Publish Date 2013-10-28 15:24
Citation Yasuda H. RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. World J Orthop 2013; 4(4): 207-217
Url http://www.wjgnet.com/2218-5836/full/v4/i4/207.htm
DOI http://dx.doi.org/10.5312/wjo.v4.i4.207
Full Article (PDF) WJO-4-207.pdf
Manuscript File 1799-review.doc
Answering Reviewers 1799-Answering reviewers.doc
Copyright License Agreement 1799-Copyright assignment.pdf
Peer-review Report 1799-Peer review(s).pdf
Scientific Editor Work List 1799-Scientific editor work list.doc